SYDNEY, Australia & INCHEON, South Korea, July 16, 2026
Organon and Samsung Bioepis have expanded their longstanding partnership through an amended Development and Commercialisation Agreement that will bring an additional biosimilar to the Australian market. The agreement further strengthens the companies’ collaboration, increasing their Australian biosimilar portfolio to four products across multiple therapeutic areas while reinforcing their shared commitment to improving patient access to affordable biologic medicines. Under the revised agreement, Organon ANZ will receive exclusive commercial rights for the new biosimilar in Australia, while Samsung Bioepis will continue to oversee development, manufacturing, and regulatory responsibilities. The expanded collaboration reflects the growing global importance of biosimilars in delivering cost-effective healthcare, increasing treatment accessibility, and supporting the long-term sustainability of Australia’s healthcare system. As healthcare systems continue to face rising costs, the partnership highlights how strategic industry collaborations can accelerate the availability of high-quality biologic alternatives without compromising safety, efficacy, or quality.
Expanded Partnership Strengthens Australia’s Biosimilar Market
The updated agreement marks another milestone in the successful global relationship between Organon and Samsung Bioepis, two companies with extensive experience in advancing biosimilar commercialization. By adding another biosimilar to Organon ANZ’s commercial portfolio, the partnership expands treatment options for Australian healthcare professionals and patients across multiple disease areas. While Samsung Bioepis will continue leading product development, manufacturing, and regulatory approvals, Organon will focus on commercializing the therapy throughout Australia. This complementary model leverages the strengths of both organizations, allowing Samsung Bioepis to maintain its reputation for biopharmaceutical innovation and manufacturing excellence, while Organon utilizes its commercial infrastructure to maximize patient access. The agreement also reinforces both companies’ broader mission of improving access to high-quality biosimilars, which continue to play an increasingly important role in modern healthcare systems by providing clinically equivalent alternatives to reference biologic medicines at lower costs.
Biosimilars Deliver Greater Access and Healthcare Savings
The expanded commercialization agreement comes as biosimilars continue to generate significant economic and clinical benefits for Australia’s healthcare system. According to industry analyses, biosimilars delivered approximately AUD 1.03 billion in Pharmaceutical Benefits Scheme (PBS) savings between 2015 and 2022, with an additional AUD 3.87 billion in projected savings between 2023 and 2027. These cost savings enable governments to reinvest healthcare resources into funding innovative therapies while maintaining broad patient access to essential medicines. Company executives emphasized that expanding biosimilar availability not only improves treatment affordability but also provides physicians and patients with more therapeutic choices across multiple disease areas. As biologic medicines continue to represent a growing share of pharmaceutical spending worldwide, biosimilars have become an increasingly important strategy for balancing innovation with healthcare sustainability. The strengthened Organon–Samsung Bioepis partnership directly supports this objective by helping ensure wider access to advanced biologic therapies while reducing financial pressure on Australia’s public healthcare system.
Advertisement
Strategic Collaboration Supports Long-Term Biopharmaceutical Growth
The expanded Australian agreement further reinforces the strategic global alliance between Organon and Samsung Bioepis, reflecting continued confidence in the long-term growth of the biosimilars market. Samsung Bioepis continues to expand its extensive pipeline spanning immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology, while Organon remains focused on increasing access to medicines across women’s health, general medicine, and biosimilars in more than 140 countries. Together, the companies are positioning themselves to meet increasing global demand for affordable biologic therapies while supporting healthcare systems facing rising treatment costs. The agreement also demonstrates the importance of international partnerships in accelerating commercialization, expanding market access, and improving patient outcomes. As biosimilars become an increasingly essential component of pharmaceutical innovation and healthcare policy, collaborations such as this continue to strengthen global access to life-changing therapies while supporting sustainable healthcare delivery for millions of patients worldwide.
Source: Organon, Samsung Bioepis press release
